Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus

Virology

Volumn 444, Issue 1-2, 2013, Pages 140-147

  Jacob, Christian L ^a   Lamorte, Louie ^a   Sepulveda, Eliud ^b   Lorenz, Ivo C ^b   Gauthier, Annick ^a   Franti, Michael ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Antibodies; Cell to cell spread; CMV; Cytomegalovirus; Hyperimmune globulin; Plaque reduction

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIGEN ANTIBODY REACTION; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; HUMAN CYTOMEGALOVIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS CULTURE; VIRUS ENTRY; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS PLAQUE; VIRUS TRANSMISSION;

ANTIBODIES; CELL-TO-CELL SPREAD; CMV; CYTOMEGALOVIRUS; HYPERIMMUNE GLOBULIN; PLAQUE REDUCTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPITHELIAL CELLS; FEMALE; HUMANS; PREGNANCY; VIRAL PLAQUE ASSAY; VIRUS INTERNALIZATION;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 84882824149     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.06.002     Document Type: Article

References (42)

1. Adler B., Scrivano L., Ruzcics Z., Rupp B., Sinzger C., Koszinowski U. Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J. Gen. Virol. 2006, 87:2451-2460.
2. Adler S.P. Editorial commentary: primary maternal cytomegalovirus infection during pregnancy: do we have a treatment option?. Clin. Infect. Dis. 2012, 55:504-506.
3. Andreoni K.A., Wang X., Huong S.M., Huang E.S. Human CMV-IGIV (CytoGam) neutralizes human cytomegalovirus (HCMV) infectivity and prevents intracellular signal transduction after HCMV exposure. Transplant Infect. Dis. 2001, 3(Suppl 2):25-30.
4. Boeckh M., Geballe A.P. Cytomegalovirus: pathogen, paradigm, and puzzle. J. Clin. Investig. 2011, 121:1673-1680.
5. Bowman J.J., Lacayo J.C., Burbelo P., Fischer E.R., Cohen J.I. Rhesus and human cytomegalovirus glycoprotein L are required for infection and cell-to-cell spread of virus but cannot complement each other. J. Virol. 2011, 85:2089-2099.
6. Burton D.R. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2002, 2:706-713.
7. Digel M., Sampaio K.L., Jahn G., Sinzger C. Evidence for direct transfer of cytoplasmic material from infected to uninfected cells during cell-associated spread of human cytomegalovirus. J. Clin. Virol. 2006, 37:10-20.
8. Forthal D.N., Phan T., Landucci G. Antibody inhibition of cytomegalovirus: the role of natural killer and macrophage effector cells. Transplant Infect. Dis. 2001, 3(Suppl 2):31-34.
9. Fouts A.E., Chan P., Stephan J.P., Vandlen R., Feierbach B. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J. Virol. 2012, 86:7444-7447.
10. Frenzel K., Ganepola S., Michel D., Thiel E., Kruger D.H., Uharek L., Hofmann J. Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines. Med. Microbiol. Immunol. 2012, 201:277-286.
11. Griffiths P.D. Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation. Lancet Infect. Dis. 2012, 12:790-798.
12. Hahn G., Revello M.G., Patrone M., Percivalle E., Campanini G., Sarasini A., Wagner M., Gallina A., Milanesi G., Koszinowski U., Baldanti F., Gerna G. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J. Virol. 2004, 78:10023-10033.
13. Hamprecht K., Steinmassl M., Einsele H., Jahn G. Discordant detection of human cytomegalovirus DNA from peripheral blood mononuclear cells, granulocytes and plasma: correlation to viremia and HCMV infection. J. Clin. Virol. 1998, 11:125-136.
14. Isaacson M.K., Compton T. Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. J. Virol. 2009, 83:3891-3903.
15. Jennings S.R., Lippe P.A., Pauza K.J., Spear P.G., Pereira L., Tevethia S.S. Kinetics of expression of herpes simplex virus type 1-specific glycoprotein species on the surfaces of infected murine, simian, and human cells: flow cytometric analysis. J. Virol. 1987, 61:104-112.
16. Jones T.R., Lee S.W., Johann S.V., Razinkov V., Visalli R.J., Feld B., Bloom J.D., O'Connell J. Specific inhibition of human cytomegalovirus glycoprotein B-mediated fusion by a novel thiourea small molecule. J. Virol. 2004, 78:1289-1300.
17. Kalil A.C., Florescu D.F. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. Crit. Care Med. 2009, 37:2350-2358.
18. Kenneson A., Cannon M.J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev. Med. Virol. 2007, 17:253-276.
19. Kimberlin D.W., Lin C.Y., Sanchez P.J., Demmler G.J., Dankner W., Shelton M., Jacobs R.F., Vaudry W., Pass R.F., Kiell J.M., Soong S.J., Whitley R.J. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J. Pediatr. 2003, 143:16-25.
20. Kinzler E.R., Compton T. Characterization of human cytomegalovirus glycoprotein-induced cell-cell fusion. J. Virol. 2005, 79:7827-7837.
21. Landry M.L., Stanat S., Biron K., Brambilla D., Britt W., Jokela J., Chou S., Drew W.L., Erice A., Gilliam B., Lurain N., Manischewitz J., Miner R., Nokta M., Reichelderfer P., Spector S., Weinberg A., Yen-Lieberman B., Crumpacker C. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob. Agents Chemother. 2000, 44:688-692.
22. Ljungman P., Larsson K., Kumlien G., Aschan J., Barkholt L., Gustafsson-Jernberg A., Lewensohn-Fuchs I., Ringden O. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors. Scand. J. Infect. Dis. 2002, 34:347-350.
23. Macagno A., Bernasconi N.L., Vanzetta F., Dander E., Sarasini A., Revello M.G., Gerna G., Sallusto F., Lanzavecchia A. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131 A complex. J. Virol. 2010, 84:1005-1013.
24. Martin J.C., Dvorak C.A., Smee D.F., Matthews T.R., Verheyden J.P. 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J. Med. Chem. 1983, 26:759-761.
25. Middeldorp J.M., Jongsma J., The T.H. Cytomegalovirus early and late membrane antigens detected by antibodies in human convalescent sera. J. Virol. 1985, 54:240-244.
26. Navarro D., Paz P., Tugizov S., Topp K., La V.J., Pereira L. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology 1993, 197:143-158.
27. Nokta M., Tolpin M.D., Nadler P.I., Pollard R.B. Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication. Antivir. Res. 1994, 24:17-26.
28. O'Connor C.M., Shenk T. Human cytomegalovirus pUS27 G protein-coupled receptor homologue is required for efficient spread by the extracellular route but not for direct cell-to-cell spread. J. Virol. 2011, 85:3700-3707.
29. Ohlin M., Silvestri M., Sundqvist V.A., Borrebaeck C.A. Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques. Clin. Diagn. Lab. Immunol. 1997, 4:107-111.
30. Ohlin M., Sundqvist V.A., Mach M., Wahren B., Borrebaeck C.A. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J. Virol. 1993, 67:703-710.
31. Planitzer C.B., Saemann M.D., Gajek H., Farcet M.R., Kreil T.R. Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations. Transplantation 2011, 92:267-270.
32. Revello M.G., Baldanti F., Percivalle E., Sarasini A., De-Giuli L., Genini E., Lilleri D., Labo N., Gerna G. In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells. J. Gen. Virol. 2001, 82:1429-1438.
33. Ryckman B.J., Jarvis M.A., Drummond D.D., Nelson J.A., Johnson D.C. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J. Virol. 2006, 80:710-722.
34. Sattentau Q. Avoiding the void: cell-to-cell spread of human viruses. Nat. Rev. Microbiol. 2008, 6:815-826.
35. Schroer J., Shenk T. Inhibition of cyclooxygenase activity blocks cell-to-cell spread of human cytomegalovirus. Proc. Natl. Acad. Sci. USA 2008, 105:19468-19473.
36. Silva M.C., Schroer J., Shenk T. Human cytomegalovirus cell-to-cell spread in the absence of an essential assembly protein. Proc. Natl. Acad. Sci. USA 2005, 102:2081-2086.
37. Sinzger C., Mangin M., Weinstock C., Topp M.S., Hebart H., Einsele H., Jahn G. Effect of serum and CTL on focal growth of human cytomegalovirus. J. Clin. Virol. 2007, 38:112-119.
38. Takada, K., Kurino, R., Torashima, T. Monoclonal Antibody Capable of Binding to Specific Discontinuous Epitope Occuring in AD1 Region of Human Cytomegalovirus gB Glycoprotein, and Antigen-binding Fragment thereof. 10758877.4(WO 2010/114106). 7-10-2010a.
39. Takada, K., Kurino, R., Torashima, T. Monoclonal Antibody Capable of Binding to Specific Discontinuous Epitpe Occurring in AD1 Region of Human Cytomegalovirus gB Glycoprotein, and Antigen-binding Fragment thereof. (US 2012/0093810 A1). 4-19-2012.
40. Takada, K., Kurino, R., Wantanabe, M. Monoclonal Antibody Capable of Binding to AD2 Region of Human Cytomegalovirus gB Glycoprotein, and Antigen-binding Fragment thereof. PCT/JP2010/056033(WO/2010/114105). 7-10-2010b.
41. Tugizov S., Maidji E., Pereira L. Role of apical and basolateral membranes in replication of human cytomegalovirus in polarized retinal pigment epithelial cells. J. Gen. Virol 1996, 77(Pt 1):61-74.
42. Wang D., Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J. Virol. 2005, 79:10330-10338.